- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01228188
Inverted ILM Repositioning as Treatment for Full Thickness Macular Holes
Surgical Inverted ILM Repositioning as Autologous Dressing for Idiopathic Full Thickness Macular Holes Treatment
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
At present, the anatomical closure rate of macular hole is around 90% using pars plana vitrectomy with ILM peeling. Improvement of visual acuity is around 80% including stage II to IV. With macular hole greater than 400 μm there is higher risk of surgical failure and visual acuity is usually less than 0.2. Large macular holes are more likely to have flat-open type closure, which is anatomical success but has limited improvement in visual acuity. Inverted ILM repositioning will form a scaffold for glial cells, which allows their migration and proliferation. This process will close the macular hole and secure it from re-opening, and will reduce the risk of flat-open type of closure.
The aim of this study is to estimate the efficiency and safety of inverted ILM repositioning in the treatment of macular hole with a minimum diameter exceeding 400 μm and compare results with the currently used methods of surgical large macular holes treatment.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jacek Robaszkiewicz, dr med.
- Phone Number: +48 604597970
- Email: vectra@izet.pl
Study Contact Backup
- Name: Urszula Karpińska, lek. med.
- Phone Number: +48 668335961
- Email: bequille@gmail.com
Study Locations
-
-
ul. Szaserów 128
-
Warsaw, ul. Szaserów 128, Poland, 04-141
- Recruiting
- Military Institute of Medcine
-
Contact:
- Połeć Dorota, mgr
- Phone Number: + 48 22 681 67 35
- Email: dpolec@wim.mil.pl
-
Principal Investigator:
- Robaszkiewicz Jacek, dr med.
-
Sub-Investigator:
- Chmielewska I. Katarzyna, lek. med.
-
Sub-Investigator:
- Karpińska Urszula, lek. med.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- full-thickness macular hole with a minimum diameter exceeding 400 μm
- BCVA of 0,3 or worse in log MAR units (<=70 ETDRS letter) and 1,6 or better in log MAR units (>=5 ETRDS letter)
- 18 years of age
- Informed consent
Exclusion Criteria:
- eyes with previous vitreous surgery
- cystoid macular edema from any cause
- post traumatic macular hole
- macular hole associated with retinal detachment
- any other ocular reason which causes the lack of improvement after macular hole surgery (e.g pigmentary abnormalities, age-related macular degeneration, corneal scarring)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Idiopathic Full Thickness Macular Hole
Eyes which do not undergo early vitrectomy at the time of enrollment.
Surgical intervention would be performed when full-thickness macular hole occurs with a minimum diameter exceeding 400 um.
|
Three port pars plana vitrectomy is performed by one surgeon (JR).
Induction of PVD is initiated by active suction with the vitrectomy probe over the ONH and continued peripherally.
First a 0.6-1.0mm
piece of ILM surrounding the macular hole is removed.
Then significant margin of ILM in macular hole circumference is released while staying connected at the base to the macularrhexis border.
Excess of ILM is trimmed.
Perfluorocarbon is administrated, stabilizing ILM flap and facilitating the flap repositioning.
Trypan Blue is used to stain the ILM.
ILM flap is pressed down over the macular hole.
The procedure is ended by SF6 gas tamponade.
Even in absence of cataract formation, a combined procedure is performed because of exact peripheral vitreous shaving and prevention of cataract formation.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Best-corrected visual acuity (BCVA), postoperative macular hole closure type
Time Frame: up to 1 week before surgery
|
BCVA for ETDRS chart (converted to logMAR) and postoperative macular hole closure type assessed by OCT: elevated-open, flat-open and flat-closed.
|
up to 1 week before surgery
|
Best-corrected visual acuity (BCVA), postoperative macular hole closure type
Time Frame: 2 weeks postoperatively ( plus or minus 1 week)
|
BCVA for ETDRS chart (converted to logMAR) and postoperative macular hole closure type assessed by OCT: elevated-open, flat-open and flat-closed.
|
2 weeks postoperatively ( plus or minus 1 week)
|
Best-corrected visual acuity (BCVA), postoperative macular hole closure type
Time Frame: 4 weeks postoperatively ( plus or minus 1 week)
|
BCVA for ETDRS chart (converted to logMAR) and postoperative macular hole closure type assessed by OCT: elevated-open, flat-open and flat-closed.
|
4 weeks postoperatively ( plus or minus 1 week)
|
Best-corrected visual acuity (BCVA), postoperative macular hole closure type
Time Frame: 6 weeks postoperatively ( plus or minus 1 week)
|
BCVA for ETDRS chart (converted to logMAR) and postoperative macular hole closure type assessed by OCT: elevated-open, flat-open and flat-closed.
|
6 weeks postoperatively ( plus or minus 1 week)
|
Best-corrected visual acuity (BCVA), postoperative macular hole closure type
Time Frame: 12 weeks postoperatively ( plus or minus 1 week)
|
BCVA for ETDRS chart (converted to logMAR) and postoperative macular hole closure type assessed by OCT: elevated-open, flat-open and flat-closed.
|
12 weeks postoperatively ( plus or minus 1 week)
|
Best-corrected visual acuity (BCVA), postoperative macular hole closure type
Time Frame: 24 weeks postoperatively ( plus or minus 1 week)
|
BCVA for ETDRS chart (converted to logMAR) and postoperative macular hole closure type assessed by OCT: elevated-open, flat-open and flat-closed.
|
24 weeks postoperatively ( plus or minus 1 week)
|
Best-corrected visual acuity (BCVA), postoperative macular hole closure type
Time Frame: 48 weeks postoperatively ( plus or minus 1 week)
|
BCVA for ETDRS chart (converted to logMAR) and postoperative macular hole closure type assessed by OCT: elevated-open, flat-open and flat-closed.
|
48 weeks postoperatively ( plus or minus 1 week)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Central Macular Thickness (CMT), Central Macular Volume
Time Frame: up to 1 week before surgery
|
Central Macular Thickness (CMT)and Central Macular Volume are assessed 1 mm and 6 mm diameter topography (OCT-SLO).
|
up to 1 week before surgery
|
Central Macular Thickness (CMT), Central Macular Volume
Time Frame: 2 weeks postoperatively (plus and minus 1 week)
|
Central Macular Thickness (CMT)and Central Macular Volume are assessed 1 mm and 6 mm diameter topography (OCT-SLO).
|
2 weeks postoperatively (plus and minus 1 week)
|
Central Macular Thickness (CMT), Central Macular Volume
Time Frame: 4 weeks postoperatively (plus and minus 1 week)
|
Central Macular Thickness (CMT)and Central Macular Volume are assessed 1 mm and 6 mm diameter topography (OCT-SLO).
|
4 weeks postoperatively (plus and minus 1 week)
|
Central Macular Thickness (CMT), Central Macular Volume
Time Frame: 6 weeks postoperatively (plus and minus 1 week)
|
Central Macular Thickness (CMT)and Central Macular Volume are assessed 1 mm and 6 mm diameter topography (OCT-SLO).
|
6 weeks postoperatively (plus and minus 1 week)
|
Central Macular Thickness (CMT), Central Macular Volume
Time Frame: 12 weeks postoperatively (plus and minus 1 week)
|
Central Macular Thickness (CMT)and Central Macular Volume are assessed 1 mm and 6 mm diameter topography (OCT-SLO).
|
12 weeks postoperatively (plus and minus 1 week)
|
Central Macular Thickness (CMT), Central Macular Volume
Time Frame: 24 weeks postoperatively (plus and minus 1 week)
|
Central Macular Thickness (CMT)and Central Macular Volume are assessed 1 mm and 6 mm diameter topography (OCT-SLO).
|
24 weeks postoperatively (plus and minus 1 week)
|
Central Macular Thickness (CMT), Central Macular Volume
Time Frame: 48 weeks postoperatively (plus and minus 1 week)
|
Central Macular Thickness (CMT)and Central Macular Volume are assessed 1 mm and 6 mm diameter topography (OCT-SLO).
|
48 weeks postoperatively (plus and minus 1 week)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jacek Robaszkiewicz, dr med., Department of Ophthalmology Military Institute of Medicine
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BW1127/10
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Macular Holes
-
Helse Stavanger HFMcGill University; Haukeland University Hospital; Royal Liverpool University... and other collaboratorsNot yet recruitingMacular Holes
-
Oriental Neurosurgery Evidence-Based-Study TeamRecruiting
-
Vienna Institute for Research in Ocular SurgeryCompleted
-
Tianjin Medical UniversityActive, not recruiting
-
Second Affiliated Hospital, School of Medicine,...Unknown
-
Federal University of São PauloUnknown
-
Kyorin UniversityCompleted
-
Fayoum UniversityResearch Institute of Ophthalmology, EgyptRecruiting
-
Minia UniversityRecruiting
-
Faculty Hospital Kralovske VinohradyCharles University, Czech RepublicRecruiting
Clinical Trials on Inverted ILM Repositioning
-
Federal University of São PauloUnknown
-
National Taiwan University HospitalCompletedRetinal Detachment | High Myopia | Macular Holes
-
University of Turin, ItalyUnknownFull Thickness Macular HoleItaly
-
University of AlexandriaCompletedMacular Holes | Retina DetachmentEgypt
-
Rush Eye AssociatesActive, not recruitingDiabetic Retinopathy Visually ThreateningMexico
-
Medical University of GrazCompletedEpiretinal Membrane of Both EyesAustria
-
Vienna Institute for Research in Ocular SurgeryCompleted
-
Duke UniversityNational Institute of Nursing Research (NINR)CompletedPressure UlcerUnited States
-
Vienna Institute for Research in Ocular SurgeryCompleted